01.01.2023 | Tracker

Product Launch Tracker: HCPs discuss pre-Christmas approvals in precision medicine, oncology and infectious disease

By Paul Cranston

Every month, CREATION.co’s tracking updates bring you the latest insights from the conversation of healthcare professionals (HCPs) across the globe discussing product launches. Discover which new drug approvals HCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.

———

Throughout December 2022 we tracked the global conversations of 1,624 HCPs who posted 2,213 English-language Twitter posts about the launches and approvals of new products.

Over the course of December, HCPs discussed several newly approved products including a gene therapy treatment for bladder cancer, a capsid inhibitor for multi-drug resistant HIV, and a faecal microbiota treatment for prevention of recurrence of clostridioides difficile infection. This year, much of the HCP conversation quietened over the Christmas and new year period, with most of the discussion occurring at the start of the month.

At the start of the month, HCPs were particularly interested in the FDA approval of the first faecal microbiota product, Rebyota, manufactured by Ferring Pharmaceuticals, which is used for the prevention of recurrence of Clostridioides difficile infection (CDI) in adult patients. HCPs considered this a significant breakthrough, beyond just the infectious disease space, suggesting that the technology may also lead to advancements in the treatment of cancer and inflammatory conditions.

Another story which generated discussion among HCPs was the FDA approval of the first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer. The product, Adstiladrin (nadofaragene firadenovec-vncg), which is also manufactured by Ferring Pharmaceuticals, was celebrated as good news for patients, with HCPs also highlighting the decades of research which led to this approval.

HCPs also expressed interest in a new precision medicine treatment for non-small cell lung cancer (NSCLC). Krazati (adagrasib), of Mirati Therapeutics, received FDA approval on December 12th for pre-treated KRAS-G12C lung cancer patients, offering a second option alongside another product, sotorasib. One HCP declared the approval as a ‘win for a subset of patients for whom progress is long overdue’.

Lastly, HCPs also commented on the approval of Gilead’s Sunlenca (lenacapavir) for patients with multi-drug resistant HIV. HCPs shared the news of the approval but were tentative to offer their opinions on the treatment, with one HCP sharing that they were waiting to hear more about the pricing of the treatment before offering further comment.

The three most shared links from HCPs discussing product launches in June were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.

Methodology

  • Using CREATION Pinpoint® the English-language Twitter conversations of HCPs globally discussing new pharmaceutical product launches and drug approvals between 1 November and 30 November 2022 were analysed in order to discover which new product launches HCPs are discussing as well as #WhatHCPsThink.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by HCPs in their Twitter conversations.
  • Between 1 November and 30 November 2022, there were 2,465 HCP mentions of new pharmaceutical product launches and drug approvals from 1,811 unique HCP authors from around the world. 

The Product Launch tracker archive

November 2022: HCPs discuss first drug to delay type 1 diabetes and the approval of world’s most expensive treatment

October 2022: HCPs share optimism for approvals in heart failure, obesity and multiple myeloma

July 2022: HCPs discuss approvals including for the prevention of smallpox and monkeypox.

June 2022: HCPs celebrate 5th agnostic approval in Cancer alongside other approvals

May 2022: HCPs excited by approvals for Eli Lilly, Novartis, Sanofi and Regeneron

April 2022: HCPs excited for BMS’ newly approved  ‘Camzyos’

March 2022: HCPs discuss approvals for several cancer treatments and a fourth dose of COVID-19 vaccines

February 2022: Approvals for Boehringer Ingelheim,Eli Lilly, and Novo Nordisk focus of HCP conversations

January 2022: HCPs celebrate new treatments for metastatic melanoma and non-small cell lung cancer

December 2021: Pre-Christmas approvals drive HCPs conversations

November 2021: HCPs welcome approvals for MSD’s Keytruda and Takeda’s Livtencity

September 2021: FDA’s Pfizer vaccine approval continues to drive HCPs conversations

August 2021: HCPs’ conversation dominated by FDA’s Pfizer vaccine approval

July 2021:  HCPs celebrate Merck & Co and Bayer approvals while discussing Modernas’s extension at length

June 2021: HCPs optimistic over Novo Nordisk and Roche approvals but still to be won over by Biogen’s aducanumab

View all articles >

Meet the Author

Paul Cranston

Paul analyses the online conversations of HCPs to provide insights for pharmaceutical companies about what HCPs think. With a background in international development, he is passionate about using data to reveal the unmet needs in healthcare communities.

In his free time, Paul can often be found either writing songs on his guitar or kicking a ball around on a football field.

Suggested next


HCPs in China are very active online

03.07.2019 | Article

HCPs in China are very active online

In China, healthcare professionals (HCPs) are active on platforms that are popular locally

By David Zhong

14.08.2020 | Case Study

Understanding HCP views and needs in the new normal customer engagement environment

Understanding HCP views and needs in the “new normal” customer engagement environment

View all articles >